As research continues into both AADvac1 and ACI-35, these active immunotherapy vaccines represent an evolving landscape in the fight against AD, reflecting the potential to harness the immune system to combat tau pathology and slow cognitive decline. Here, MAPT is linked to Mental deterioration.